Wen-Tyng Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wen-Tyng Kang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Haizhou Li
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Guangzhou 511436, China
1 shared publication Rongcui Zhong
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Guangzhou 511436, China
1 shared publicationShanfang Fang
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Guangzhou 511436, China
1 shared publication- Shouping Liu
Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, Affiliated Qingyuan Hospital, and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China
1 shared publication - Shuimu Lin
Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, Affiliated Qingyuan Hospital, and School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China
1 shared publication Weijie Wen
Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences and the Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Guangzhou 511436, China
1 shared publication
Latest Publications
- Open Access
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadt4723
Development of xanthone derivatives as effective broad-spectrum antimicrobials: Disrupting cell wall and inhibiting DNA synthesis
Discovering potent antibiotics is of critical importance due to the substantial increases of microbial resistance. Xanthones are intriguing sources of antimicrobials, despite a scarcity of extensive investigations into their mechanisms of action. Here, we reported the development of a series of xanthone derivatives, among which compound XT17 displayed strong broad-spectrum antibacterial activity, weak hemolytic activity, and low cytotoxicity against mammalian cell lines, low frequencies of drug resistance, and potent in vivo efficacy in Staphylococcu aureus – or Pseudomonas aeruginosa –induced murine corneal infection models. Compound XT17 presented a multifaceted mode of actions, involving the disruption of cell wall by interacting with lipoteichoic acid or lipopolysaccharides and the suppression of DNA synthesis. A further docking study confirmed the capability of compound XT17 to form a stable complex with the bacterial gyrase enzyme. This work could offer an innovative design strategy for developing broad-spectrum therapeutic agents against drug-resistant bacteria.
- 7 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (10) , eadt4723
Open AccessDevelopment of xanthone derivatives as effective broad-spectrum antimicrobials: Disrupting cell wall and inhibiting DNA synthesis
Discovering potent antibiotics is of critical importance due to the substantial increases of microbial resistance. Xanthones are intriguing sources of antimicrobials, despite a scarcity of extensive investigations into their mechanisms of action. Here, we reported the development of a series of xanthone derivatives, among which compound XT17 displayed strong broad-spectrum antibacterial activity, weak hemolytic activity, and low cytotoxicity against mammalian cell lines, low frequencies of drug resistance, and potent in vivo efficacy in Staphylococcu aureus – or Pseudomonas aeruginosa –induced murine corneal infection models. Compound XT17 presented a multifaceted mode of actions, involving the disruption of cell wall by interacting with lipoteichoic acid or lipopolysaccharides and the suppression of DNA synthesis. A further docking study confirmed the capability of compound XT17 to form a stable complex with the bacterial gyrase enzyme. This work could offer an innovative design strategy for developing broad-spectrum therapeutic agents against drug-resistant bacteria.